Skip to Main Content

Paper Details

Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Neuro Oncol
9
2023
NF1, PN, Participants, Selumetinib, Tumor pain, children, neurofibromatosis type 1, participants, patient, plexiform neurofibromas, selumetinib, tumor, tumor pain
Author NameAffiliation
Seth M SteinbergCenter for Cancer Research, National Cancer Institute
Seth M SteinbergCenter for Cancer Research, National Cancer Institute
Michael J FisherChildren's Hospital of Philadelphia
Jaishri O BlakeleyJohns Hopkins University
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Brigitte C WidemannCenter for Cancer Research, National Cancer Institute
  • 1 - 7

Datasets

Release 1.2